During the past decade, MC Asklepii OOD conducted 4 clinical trials. In the 10-year time frame, 4 clinical trials started and 2 clinical trials were completed, i.e. on average, 50% percent of trials that started reached the finish line to date. In the past 5 years, 1 clinical trials started and 2 clinical trials were completed. i.e. 200% of trials that started reached the finish line.

According to Clinical.Site data, the most researched conditions in "MC Asklepii OOD" are "Dermatitis, Atopic" (2 trials), "Atopic Dermatitis" (1 trials), "Dermatitis" (1 trials), "Eczema" (1 trials) and "Genetic Diseases, Inborn" (1 trials). Many other conditions were trialed in "MC Asklepii OOD" in a lesser frequency.

Most popular intervention types in "MC Asklepii OOD" are "Drug" (4 trials) and "Combination Product" (1 trials). Other intervention types were less common.

The name of intervention was led by "Abrocitinib 200 mg" (2 trials), "Placebo" (2 trials), "Abrocitinib 100 mg" (1 trials), "Dupilumab 300 mg" (1 trials) and "PF-04965842 100 mg" (1 trials). Other intervention names were less common.

The vast majority of trials in "MC Asklepii OOD" are 3 trials for "All" genders and 1 trials for "Female" genders.

Currently, there are NaN active trials in "MC Asklepii OOD". undefined are not yet recruiting, undefined are recruiting, 1 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 3 completed trials in MC Asklepii OOD, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in MC Asklepii OOD, 0 "Phase 1" clinical trials were conducted, 0 "Phase 2" clinical trials and 4 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".